SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Zim $4.5 billion bidder faces foreclosure on his home

NextVision insiders cash out $200 million in share sale

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

Electra Real Estate CEO: “The $7 trillion US rental housing market is the place to be”

Buzz

Most popular

Daily

Weekly

1

Jewish family from Mexico donates NIS 200 million to establish Israel's largest rehabilitation hospital

2

After raising $20 million, collapsed startup Swish.ai sells to Unframe for just $150,000

3

Echo: “Employees have become very good at identifying performative culture”

4

After PTSD and years of insomnia, Israeli founder raises $6.5 million to improve sleep through scent

5

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

Generics

6 stories about Generics

קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene

With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year

ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer

Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800

קאר שולץ מנכל טבע

Teva to Relocate U.S. Headquarters to New Jersey

08.07.18|Lilach Baumer

In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt

קאר שולץ מנכל טבע

Goldman Sachs Sees 16% Upside in Teva Stock

26.06.18|Dror Reich

Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price

יו"ר ועד עובדי טבע כפר סבא אלירן קוזליק

In Protest of New Bonus Plan, Teva Sued by Israeli Employees

15.03.18|Dror Reich

After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February

מנכ"ל טבע גנריקה סיגורדור סיגי אולפסון

Drugmaker Hikma Appoints Former Teva Executive as CEO

20.02.18|Asaf Shalev

The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit